{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:34:17Z","timestamp":1740141257666,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T00:00:00Z","timestamp":1572220800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T00:00:00Z","timestamp":1572220800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Conventional assays to titrate polioviruses usually test serial dilutions inoculated into replicate cell cultures to determine a 50% cytopathic endpoint, a process that is both time-consuming and laborious. Such a method is still used to measure potency of live Oral Poliovirus Vaccine during vaccine development and production and in some clinical trials. However, the conventional method is not suited to identify and titrate virus in the large numbers of fecal samples generated during clinical trials. Determining titers of each of the three Sabin strains co-existing in Oral Poliovirus Vaccine presents an additional challenge.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A new assay using quantitative multiplex polymerase chain reaction as an endpoint instead of cytopathic effect was developed to overcome these limitations. In the multiplex polymerase chain reaction-based titration assay, cell cultures were infected with serial dilutions of test samples, lysed after two-day incubation, and subjected to a quantitative multiplex one-step reverse-transcriptase polymerase chain reaction. All three serotypes of poliovirus were identified in single samples and titers calculated. The multiplex polymerase chain reaction-based titration assay was reproducible, robust and sensitive. Its lower limits of titration for three Sabin strains were 1\u20135 cell culture 50% infectious doses per ml. We prepared different combinations of three Sabin strains and compared titers obtained with conventional and multiplex polymerase chain reaction-based titration assays. Results of the two assays correlated well and showed similar results and sensitivity. Multiplex polymerase chain reaction-based titration assay was completed in two to 3 days instead of 10 days for the conventional assay.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The multiplex polymerase chain reaction-based titration (MPBT) is the first quantitative assay that identifies and titrates each of several different infectious viruses simultaneously in a mixture. It is suitable to identify and titrate polioviruses rapidly during the vaccine manufacturing process as a quality control test, in large clinical trials of vaccines, and for environmental surveillance of polioviruses. The MPBT assay can be automated for high-throughput implementation and applied for other viruses including those with no cytopathic effect.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12985-019-1233-6","type":"journal-article","created":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T17:05:08Z","timestamp":1572282308000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Multiplex PCR-based titration (MPBT) assay for determination of infectious titers of the three Sabin strains of live poliovirus vaccine"],"prefix":"10.1186","volume":"16","author":[{"given":"Hasmik","family":"Manukyan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira","family":"Rodionova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Zagorodnyaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsai-Lien","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantin","family":"Chumakov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0110-5504","authenticated-orcid":false,"given":"Majid","family":"Laassri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,10,28]]},"reference":[{"key":"1233_CR1","unstructured":"WHO. Polio vaccines: WHO position paper - March 2016. Weekly epidemiological record. Geneva: WHO Press; 2016. p. 145\u201368."},{"issue":"6","key":"1233_CR2","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1093\/infdis\/162.6.1291","volume":"162","author":"H Faden","year":"1990","unstructured":"Faden H, Modlin JF, Thoms ML, McBean AM, Ferdon MB, Ogra PL. Comparative evaluation of immunization with live attenuated and enhanced-potency inactivated trivalent poliovirus vaccines in childhood: systemic and local immune responses. J Infect Dis. 1990;162(6):1291\u20137 PubMed PMID: 2172403.","journal-title":"J Infect Dis"},{"key":"1233_CR3","unstructured":"This-week. Polio this week as of 18 October 2017. This Week \u2013 GPEI - Global Polio Eradication Initiative. 2017. http:\/\/polioeradication.org\/polio-today\/polio-now\/this-week\/ ."},{"issue":"Suppl 1","key":"1233_CR4","doi-asserted-by":"publisher","first-page":"S283","DOI":"10.1093\/infdis\/jiu295","volume":"210","author":"CC Burns","year":"2014","unstructured":"Burns CC, Diop OM, Sutter RW, Kew OM. Vaccine-derived polioviruses. J Infect Dis. 2014;210(Suppl 1):S283\u201393. https:\/\/doi.org\/10.1093\/infdis\/jiu295 PubMed PMID: 25316847.","journal-title":"J Infect Dis"},{"key":"1233_CR5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","volume":"59","author":"OM Kew","year":"2005","unstructured":"Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu Rev Microbiol. 2005;59:587\u2013635. https:\/\/doi.org\/10.1146\/annurev.micro.58.030603.123625 Epub 2005\/09\/13. PubMed PMID: 16153180.","journal-title":"Annu Rev Microbiol"},{"issue":"Suppl 1","key":"1233_CR6","doi-asserted-by":"publisher","first-page":"S380","DOI":"10.1093\/infdis\/jiu184","volume":"210","author":"LR Platt","year":"2014","unstructured":"Platt LR, Estivariz CF, Sutter RW. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden. J Infect Dis. 2014;210(Suppl 1):S380\u20139. https:\/\/doi.org\/10.1093\/infdis\/jiu184 PubMed PMID: 25316859.","journal-title":"J Infect Dis"},{"key":"1233_CR7","first-page":"A69","volume-title":"Sixty-Ninth World Health Assembly, Provisional Agenda Item 14.5. Poliomyelitis","author":"WHO","year":"2016","unstructured":"WHO. Sixty-Ninth World Health Assembly, Provisional Agenda Item 14.5. Poliomyelitis; 2016. p. A69\u201325."},{"issue":"9953","key":"1233_CR8","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/S0140-6736(14)60934-X","volume":"384","author":"J John","year":"2014","unstructured":"John J, Giri S, Karthikeyan AS, Iturriza-Gomara M, Muliyil J, Abraham A, et al. Effect of a single inactivated poliovirus vaccine dose on intestinal immunity against poliovirus in children previously given oral vaccine: an open-label, randomised controlled trial. Lancet. 2014;384(9953):1505\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(14)60934-X PubMed PMID: 25018120.","journal-title":"Lancet"},{"issue":"suppl_1","key":"1233_CR9","doi-asserted-by":"publisher","first-page":"S40","DOI":"10.1093\/infdis\/jiw571","volume":"216","author":"J Rubin","year":"2017","unstructured":"Rubin J, Ottosen A, Ghazieh A, Fournier-Caruana J, Ntow AK, Gonzalez AR. Managing the planned cessation of a global supply market: lessons learned from the global cessation of the trivalent oral poliovirus vaccine market. J Infect Dis. 2017;216(suppl_1):S40\u2013S5. https:\/\/doi.org\/10.1093\/infdis\/jiw571 PubMed PMID: 28838167; PubMed Central PMCID: PMCPMC5853836.","journal-title":"J Infect Dis"},{"issue":"3","key":"1233_CR10","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/infdis\/jix556","volume":"217","author":"EB Brickley","year":"2018","unstructured":"Brickley EB, Strauch CB, Wieland-Alter WF, Connor RI, Lin S, Weiner JA, et al. Intestinal immune responses to type 2 oral polio vaccine (OPV) challenge in infants previously immunized with bivalent OPV and either high-dose or standard inactivated polio vaccine. J Infect Dis. 2018;217(3):371\u201380. https:\/\/doi.org\/10.1093\/infdis\/jix556 PubMed PMID: 29304199; PubMed Central PMCID: PMCPMC5853416.","journal-title":"J Infect Dis"},{"issue":"suppl_1","key":"1233_CR11","doi-asserted-by":"publisher","first-page":"S176","DOI":"10.1093\/infdis\/jix108","volume":"216","author":"KM Thompson","year":"2017","unstructured":"Thompson KM, Duintjer Tebbens RJ. Lessons from the polio endgame: overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission. J Infect Dis. 2017;216(suppl_1):S176\u2013S82. https:\/\/doi.org\/10.1093\/infdis\/jix108 PubMed PMID: 28838194; PubMed Central PMCID: PMCPMC5853387.","journal-title":"J Infect Dis"},{"issue":"12","key":"1233_CR12","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1016\/S1473-3099(16)30169-4","volume":"16","author":"PF Wright","year":"2016","unstructured":"Wright PF, Connor RI, Wieland-Alter WF, Hoen AG, Boesch AW, Ackerman ME, et al. Vaccine-induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants. Lancet Infect Dis. 2016;16(12):1377\u201384. https:\/\/doi.org\/10.1016\/S1473-3099(16)30169-4 PubMed PMID: 27638357; PubMed Central PMCID: PMCPMC5611465.","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"1233_CR13","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/S1473-3099(15)00488-0","volume":"16","author":"X Saez-Llorens","year":"2016","unstructured":"Saez-Llorens X, Clemens R, Leroux-Roels G, Jimeno J, Clemens SA, Weldon WC, et al. Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial. Lancet Infect Dis. 2016;16(3):321\u201330. https:\/\/doi.org\/10.1016\/S1473-3099(15)00488-0 PubMed PMID: 26719058.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"1233_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S0092-1157(83)80031-6","volume":"11","author":"P Albrecht","year":"1983","unstructured":"Albrecht P, Enterline JC, Boone EJ, Klutch MJ. Poliovirus and polio antibody assay in HEp-2 and Vero cell cultures. J Biol Stand. 1983;11(2):91\u20137 PubMed PMID: 6306012.","journal-title":"J Biol Stand"},{"issue":"2","key":"1233_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0166-0934(84)90004-1","volume":"9","author":"E Bey","year":"1984","unstructured":"Bey E, Golombick T. A comparison of three methods for titration of poliovirus vaccines. J Virol Methods. 1984;9(2):123\u201330 PubMed PMID: 6096387.","journal-title":"J Virol Methods"},{"issue":"2","key":"1233_CR16","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/S0092-1157(85)80022-6","volume":"13","author":"DI Magrath","year":"1985","unstructured":"Magrath DI, Seagroatt V. The standardization of infectivity titrations of poliovaccines--a WHO collaborative study. J Biol Stand. 1985;13(2):159\u201366 PubMed PMID: 3997898.","journal-title":"J Biol Stand"},{"issue":"1","key":"1233_CR17","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/btpr.522","volume":"27","author":"R Bareither","year":"2011","unstructured":"Bareither R, Pollard D. A review of advanced small-scale parallel bioreactor technology for accelerated process development: current state and future need. Biotechnol Prog. 2011;27(1):2\u201314. https:\/\/doi.org\/10.1002\/btpr.522 PubMed PMID: 21312350.","journal-title":"Biotechnol Prog"},{"issue":"1","key":"1233_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jviromet.2012.12.015","volume":"189","author":"M Laassri","year":"2013","unstructured":"Laassri M, Dipiazza A, Bidzhieva B, Zagorodnyaya T, Chumakov K. Quantitative one-step RT-PCR assay for rapid and sensitive identification and titration of polioviruses in clinical specimens. J Virol Methods. 2013;189(1):7\u201314. https:\/\/doi.org\/10.1016\/j.jviromet.2012.12.015 PubMed PMID: 23305817.","journal-title":"J Virol Methods"},{"key":"1233_CR19","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jviromet.2018.06.009","volume":"259","author":"H Manukyan","year":"2018","unstructured":"Manukyan H, Zagorodnyaya T, Ruttimann R, Manor Y, Bandyopadhyay A, Shulman L, et al. Quantitative multiplex one-step RT-PCR assay for identification and quantitation of Sabin strains of poliovirus in clinical and environmental specimens. J Virol Methods. 2018;259:74\u201380. https:\/\/doi.org\/10.1016\/j.jviromet.2018.06.009 PubMed PMID: 29920299.","journal-title":"J Virol Methods"},{"issue":"10040","key":"1233_CR20","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/S0140-6736(16)00703-0","volume":"388","author":"EJ Asturias","year":"2016","unstructured":"Asturias EJ, Bandyopadhyay AS, Self S, Rivera L, Saez-Llorens X, Lopez E, et al. Humoral and intestinal immunity induced by new schedules of bivalent oral poliovirus vaccine and one or two doses of inactivated poliovirus vaccine in Latin American infants: an open-label randomised controlled trial. Lancet. 2016;388(10040):158\u201369. https:\/\/doi.org\/10.1016\/S0140-6736(16)00703-0 PubMed PMID: 27212429.","journal-title":"Lancet"},{"key":"1233_CR21","unstructured":"Technical Report Series No. 673 [Internet]. Geneva: WHO; 1982. Available from: http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/41534\/WHO_TRS_673.pdf?sequence=1 ."},{"issue":"8","key":"1233_CR22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1073\/pnas.38.8.747","volume":"38","author":"R Dulbecco","year":"1952","unstructured":"Dulbecco R. Production of plaques in monolayer tissue cultures by single particles of an animal virus. Proc Natl Acad Sci U S A. 1952;38(8):747\u201352 PubMed PMID: 16589172; PubMed Central PMCID: PMCPMC1063645.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"1233_CR23","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1016\/j.vaccine.2009.11.049","volume":"28","author":"D Forcic","year":"2010","unstructured":"Forcic D, Kosutic-Gulija T, Santak M, Jug R, Ivancic-Jelecki J, Markusic M, et al. Comparisons of mumps virus potency estimates obtained by 50% cell culture infective dose assay and plaque assay. Vaccine. 2010;28(7):1887\u201392. https:\/\/doi.org\/10.1016\/j.vaccine.2009.11.049 PubMed PMID: 19961964.","journal-title":"Vaccine."},{"key":"1233_CR24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/978-1-62703-601-6_12","volume":"1064","author":"D Lieber","year":"2013","unstructured":"Lieber D, Bailer SM. Determination of HSV-1 infectivity by plaque assay and a luciferase reporter cell line. Methods Mol Biol. 2013;1064:171\u201381. https:\/\/doi.org\/10.1007\/978-1-62703-601-6_12 PubMed PMID: 23996257.","journal-title":"Methods Mol Biol"},{"issue":"6","key":"1233_CR25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.biologicals.2012.09.005","volume":"40","author":"M Simoes","year":"2012","unstructured":"Simoes M, Camacho LA, Yamamura AM, Miranda EH, Cajaraville AC, da Silva Freire M. Evaluation of accuracy and reliability of the plaque reduction neutralization test (micro-PRNT) in detection of yellow fever virus antibodies. Biologicals. 2012;40(6):399\u2013404. https:\/\/doi.org\/10.1016\/j.biologicals.2012.09.005 PubMed PMID: 23034357.","journal-title":"Biologicals"},{"issue":"4","key":"1233_CR26","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1093\/genetics\/157.4.1403","volume":"157","author":"LA Cooper","year":"2001","unstructured":"Cooper LA, Scott TW. Differential evolution of eastern equine encephalitis virus populations in response to host cell type. Genetics. 2001;157(4):1403\u201312 PubMed PMID: 11290699; PubMed Central PMCID: PMCPMC1461603.","journal-title":"Genetics"},{"issue":"2","key":"1233_CR27","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S0166-0934(01)00316-0","volume":"96","author":"DD LaBarre","year":"2001","unstructured":"LaBarre DD, Lowy RJ. Improvements in methods for calculating virus titer estimates from TCID50 and plaque assays. J Virol Methods. 2001;96(2):107\u201326 PubMed PMID: 11445142.","journal-title":"J Virol Methods"},{"issue":"12","key":"1233_CR28","doi-asserted-by":"publisher","first-page":"e1002390","DOI":"10.1371\/journal.ppat.1002390","volume":"7","author":"CY Lee","year":"2011","unstructured":"Lee CY, Kam YW, Fric J, Malleret B, Koh EG, Prakash C, et al. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. PLoS Pathog. 2011;7(12):e1002390. https:\/\/doi.org\/10.1371\/journal.ppat.1002390 PubMed PMID: 22144891; PubMed Central PMCID: PMCPMC3228792.","journal-title":"PLoS Pathog"},{"issue":"4","key":"1233_CR29","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1128\/JVI.77.4.2701-2708.2003","volume":"77","author":"A Lopez-Bueno","year":"2003","unstructured":"Lopez-Bueno A, Mateu MG, Almendral JM. High mutant frequency in populations of a DNA virus allows evasion from antibody therapy in an immunodeficient host. J Virol. 2003;77(4):2701\u20138 PubMed PMID: 12552010; PubMed Central PMCID: PMCPMC141124.","journal-title":"J Virol"},{"issue":"3\u20134","key":"1233_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/BF01378972","volume":"84","author":"A Takenaka","year":"1985","unstructured":"Takenaka A, Gibbs CJ Jr, Gajdusek DC. Antiviral neutralizing antibody to Hantaan virus as determined by plaque reduction technique. Arch Virol. 1985;84(3\u20134):197\u2013206 PubMed PMID: 2859845.","journal-title":"Arch Virol"},{"issue":"1","key":"1233_CR31","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jviromet.2009.03.007","volume":"159","author":"A Roldao","year":"2009","unstructured":"Roldao A, Oliveira R, Carrondo MJ, Alves PM. Error assessment in recombinant baculovirus titration: evaluation of different methods. J Virol Methods. 2009;159(1):69\u201380. https:\/\/doi.org\/10.1016\/j.jviromet.2009.03.007 PubMed PMID: 19442848.","journal-title":"J Virol Methods"},{"key":"1233_CR32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/978-1-59745-170-3_3","volume":"485","author":"Y Gao","year":"2009","unstructured":"Gao Y, Nankya I, Abraha A, Troyer RM, Nelson KN, Rubio A, et al. Calculating HIV-1 infectious titre using a virtual TCID(50) method. Methods Mol Biol. 2009;485:27\u201335. https:\/\/doi.org\/10.1007\/978-1-59745-170-3_3 PubMed PMID: 19020816.","journal-title":"Methods Mol Biol"},{"issue":"6","key":"1233_CR33","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1128\/JCM.00761-13","volume":"51","author":"SV Nadgir","year":"2013","unstructured":"Nadgir SV, Hensler HR, Knowlton ER, Rinaldo CR, Rappocciolo G, Jenkins FJ. Fifty percent tissue culture infective dose assay for determining the titer of infectious human herpesvirus 8. J Clin Microbiol. 2013;51(6):1931\u20134. https:\/\/doi.org\/10.1128\/JCM.00761-13 PubMed PMID: 23554189; PubMed Central PMCID: PMCPMC3716109.","journal-title":"J Clin Microbiol"},{"key":"1233_CR34","unstructured":"European-Pharmacopoiea. Poliomyelitis vaccine (inactivated). 7th ed. Strasbourg: EuropeanPharmacopoiea; 2011. p. 815\u20137."},{"issue":"2","key":"1233_CR35","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0092-1157(89)90004-8","volume":"17","author":"C Singer","year":"1989","unstructured":"Singer C, Knauert F, Bushar G, Klutch M, Lundquist R, Quinnan GV Jr. Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies. J Biol Stand. 1989;17(2):137\u201350 PubMed PMID: 2541133.","journal-title":"J Biol Stand"},{"key":"1233_CR36","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/BF01863914","volume":"162","author":"G Karber","year":"1931","unstructured":"Karber G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Archiv f experiment Pathol u Pharmakol. 1931;162:480\u20133. https:\/\/doi.org\/10.1007\/BF01863914 .","journal-title":"Archiv f experiment Pathol u Pharmakol"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-019-1233-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12985-019-1233-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12985-019-1233-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T21:10:13Z","timestamp":1664745013000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/s12985-019-1233-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,28]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1233"],"URL":"https:\/\/doi.org\/10.1186\/s12985-019-1233-6","relation":{},"ISSN":["1743-422X"],"issn-type":[{"type":"electronic","value":"1743-422X"}],"subject":[],"published":{"date-parts":[[2019,10,28]]},"assertion":[{"value":"1 May 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Anonymized stool samples used in this work were collected from a clinical trial of OPV2 (\u201cFighting Infectious Diseases in Emerging Countries\u201d [FIDEC]) [] that was approved by ethics committees and as appropriate by National Regulatory Authorities, the Colorado Multiple Institutional Review Board, and the Western Institutional Review Board.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"122"}}